Connect with us

Health

Phoenix Life Sciences International Limited (OTCMKTS:PLSI): The New Kid on the Cannabis Block

Published

on

Phoenix Life Sciences International Limited (OTCMKTS:PLSI) shares continue to look ripe for some potential action as the stock holds key support at the 200-day moving average in recent sessions. The company is a relatively new player on the cannabis playing field, but one with obviously very big plans. That is further supported by its news out on Wednesday.

Specifically, the company just announced its new Board of Directors and executive team, which includes some pretty impressive characters. “We have strategically selected these dedicated professionals based upon their ability to deliver and find creative solutions to help the company grow,” said Chief Executive Officer of Phoenix Life Martin Tindall. “I look forward to working with this talented team and know that we will continue to be successful in our commitment to the vision of life-enhancement through better healthcare.”

Phoenix Life Sciences International Limited (OTCMKTS:PLSI) is an adaptive healthcare solutions company. PLSI is in business to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders.

The company strives to create partnerships and integrate these programs for human health into communities worldwide as part of its Global Health Initiative.

According to company materials, “Phoenix Life Sciences International Limited is headquartered in Denver, Colorado. Over the past four years, many of our partner organizations have worked hard to develop and access a broad range of industry and pharmacology specialists. The partnership includes botanists, biologists, industrial and organic chemists, medical doctors, researchers, packagers and distributors. We are delighted to announce that in September 2018 we merged many of these partnerships and affiliations together under the name Phoenix Life Sciences International Limited. Without the support and collaboration of many individuals, this vision wouldn’t have been realized and we thank them for their global vision.”

 

A Solid Foundation

“It was important for Phoenix Life Sciences International to select individuals that believe in our mission to create a global platform for the reintroduction of plant-based pharmaceuticals, including medical cannabis products, into mainstream healthcare,” continued Tindall. “This new team is comprised of key leaders with decades of cumulative years of experience and I feel confident that we will make great strides together.”

Most centrally, Martin Tindall has been appointed as the company’s Chief Executive Officer.

According to the release, “He has held various roles including Chief Information Officer at Bartercard and Executive Director of Kronos International Investments, working with clients in a wide range of industries. Tindall founded Phoenix Life and its related companies after losing his father to chemotherapy in treating pancreatic cancer. Today, driving the vision for a better future for healthcare, Tindall leads the Phoenix Team.”

At this time, carrying a capital value in the market of $523.28k, PLSI has virtually no cash on the books, which compares with about $2.1M in total current liabilities. One should also note that debt has been growing over recent quarters.

However, the growth that is starting to heat up the top line grants speculators some interesting fuel to see the potential upside ahead: y/y quarterly revenues are growing at 541.4%.

We will update the story again soon as developments transpire.

Business

Why CV Sciences Inc (OTCMKTS:CVSI) Shares are Surging Again

Published

on

Even though it is under fire from law firms and battling poor sentiment, CV Sciences Inc (OTCMKTS:CVSI) shares have started to surge back to the upside in recent action, crossing back above the stock’s 50-day moving average to close out last week. To help drive the story, the company recently announced that it has introduced PlusCBD Oil Gummies at the Natural Product Expo East 2018.

A look at the company’s press release from late September reveals additional details: “A new category of PlusCBD Oil products, PlusCBD Oil Gummies are offered in two tasty flavors, Cherry Mango and Citrus Punch. A line extension of our Gold Formula line with no artificial ingredients, each gummy contains 5 mg of CBD and a mere 1.5 g of sugar. Gluten free, vegan friendly, and non-GMO, these new products support healthy balance of the body and mind.”

CV Sciences Inc (OTCMKTS:CVSI) bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.

Moreover, CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

CV Sciences Inc (OTCMKTS:CVSI) pulled in sales of $12.3M in its last reported quarterly financials, representing top line growth of 202.5%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($7.2M against $3M).

 

Surging Back

Shares of CVSI have powered higher over the past month, rallying roughly 52% in that time on strong overall action. Moreover, the listing has registered increased average transaction volume recently, with the past month seeing 15% beyond what we have been seeing over the larger time frame.

The action has taken the stock back above its critical 50-day moving average. The most recent press from the company, as discussed above, is its announcement that it has introduced PlusCBD Oil Gummies at the Natural Product Expo East 2018.

“We are pleased to introduce PlusCBD Oil Gummies to our existing line of industry leading hemp extract products that include balms, sprays, drops, capsules, and softgels,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are committed to innovation of our PlusCBD Oil products, and as the demand for CBD infused products continues to grow, it is important to expand our wide variety of products to suit all customer preferences. We foresee PlusCBD Oil Gummies being a solid revenue driving category for our Company.”

Continue Reading

Business

What May Spur the Next Breakout in Aphria Inc (OTCMKTS:APHQF)?

Published

on

Aphria Inc (OTCMKTS:APHQF) shares have been tracing out an interesting sideways trading range over the past month. That range is starting to come to a head in recent trade. The trend is clearly to the upside on almost every timeframe, and trend traders should be on the lookout for catalysts that can serve to push that extension.

Further pushing the story forward, the company just announced that it has closed the acquisition of LATAM Holdings Inc. from Scythian Biosciences. According to the release, “The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018.”

Aphria Inc (OTCMKTS:APHQF) commands a market cap of $3.22B as a leading global cannabis company driven by “an unrelenting commitment to our people, product quality and innovation.”

Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market.

The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. “Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.”

The company touts itself as one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. The company is truly powered by sunlight, allowing for the most natural growing conditions available. “We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.”

Aphria Inc (OTCMKTS:APHQF) has been raking in the cash, with $9.4 million coming in its quarter-ended May 31. Revenues are growing at a robust 110%. The company is also sitting on a strong balance sheet, with total assets now above $1 billion against total debt at just above $115 million.

 

New Catalysts in Technical Context

As discussed above, APHQF just announced that it has closed the acquisition of LATAM Holdings Inc. from Scythian Biosciences.

“Aphria continues to execute on its plans for strategic international expansion, including in Latin America and the Caribbean,” said Vic Neufeld, Chief Executive Officer of Aphria. “With a combined population of nearly 640 million, and with significant momentum from numerous countries introducing new or modernizing existing medical cannabis legislation, the region represents a significant opportunity for long-term growth. It also hosts some of the most favourable conditions for cultivating high-quality medical cannabis at substantial efficiencies – ideal for both regional supply and export opportunities. This acquisition firmly cements Aphria’s leadership in the region and on the global cannabis stage.”

Shares continue to hold up in a range over the past 3 weeks, with a possible breakout lined up if and when we see the stock push back above resistance in the $16/share area.

Continue Reading

Business

How Recent Results from Aurora Cannabis Inc (OTCMKTS:ACBFF) Suggest Bigger Things to Come

Published

on

Aurora Cannabis Inc (OTCMKTS:ACBFF) continues to be a clear market leader in terms of raw access to growth in the Canadian cannabis sector as we approach the full adult-use legalization date later this month. This was again on display last week as the company hit the tape with its latest quarterly report.

“Aurora made substantial progress toward our strategic goal of becoming the global scale and margin leader in the cannabis industry, establishing a vertically integrated company with a broadly diversified product offering with a large global footprint,” said Terry Booth, CEO of Aurora. “Our high-pace, consistent execution has enabled us to complete a number of transformative acquisitions, bringing together industry-leading companies in terms of scale, quality, efficiencies, plant and medical science, product development and innovation, brands, and international distribution.”

Aurora Cannabis Inc (OTCMKTS:ACBFF) is one of the most widely diversified players in the cannabis space due to its powerful strategic investments.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector.

The company has invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

However, just drilling down into its core cannabis production operations, through Aurora Cannabis Enterprises Inc, trumpets itself as “one of the world’s largest and leading cannabis companies” and a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).

The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as Aurora Mountain, is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island.

Aurora Cannabis Inc (OTCMKTS:ACBFF) is pulling in trailing 12-month revenues of $42M, with revenues of $19.2 million for the quarter ended June 30, which is up 223% compared to the same period in 2017. In addition, the company is sitting on a mountain of assets, with its latest data showing over $167 million on the balance sheet against just $57M in debt.

 

Aces Up

As discussed above, ACBFF shares continue to benefit from the company’s growth along with its extremely rich and diversified base of strategic investments.

Mr. Booth added, “With coast-to-coast supply arrangements, and our strategic investment in Alcanna, we are very well positioned to capitalize on the significant adult consumer use opportunity in Canada. With reported Q4 revenues of $19.1 million, pro-forma Q4 revenues of over $33.1 million, and production capacity scaling up rapidly, we anticipate accelerated revenue growth during fiscal 2019. We have invested heavily in our organizational capabilities, including sales, marketing, and corporate talent and capacity, to ensure we will continue to drive strong and sustainable long-term growth.”

The stock has been very strong since securing technical support back in early August when shares briefly dipped down under the $5/share level for a few days. When that level was retaken by bulls, it was truly off to the races, and this quarterly report helps to explain why.

Mr. Booth concluded, “Today, Aurora ticks all the boxes for sustainable success and leadership in the cannabis industry. Aurora is capitalizing on a once in a lifetime opportunity, and establishing new industry standards in terms of execution, science, cultivation, international expansion and product development that position us exceptionally well to do so. We are very proud of our achievements over the past year, and we look forward to fiscal 2019 as we continue to execute.”

Continue Reading
Advertisement
Advertisement

TRENDING STORIES

INDUSTRIAL HEMP1 month ago

Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit

Post Views: 288 Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of...

INDUSTRIAL HEMP1 month ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Launches Expands Its Footprint In Florida With New Medical Marijuana dispensary in Gainesville

Post Views: 302 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) recently announced that it launched a new outlet in Gainesville, making...

INDUSTRIAL HEMP1 month ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Gets Greenlight To Expand Its Foreign Private ISSUER Threshold

Post Views: 274 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) revealed earlier this month that its Board of Directors has approved...

INDUSTRIAL HEMP1 month ago

Generex Biotechnology Corporation (OTCMKTS:GNBT) Adds MediSource Partners And Pantheon Medical To Its NuGenerex Family Of Subsidiaries

Post Views: 225 Generex biotechnology Corporation (OTCMKTS:GNBT) has welcomed MediSource Partners to its family of subsidiaries and introduced Pantheon Medical...

INDUSTRIAL HEMP1 month ago

CBD Unlimited Inc. (OTCMKTS:EDXC) Enhances Its Convenience Store Program Targeting 300 Stores

Post Views: 224 CBD Unlimited Inc. (OTCMKTS:EDXC), formerly Endexx Corporation, has announced an enhanced convenient store launch program. The provider...

INDUSTRIAL HEMP1 month ago

Cronos Group Inc. (NASDAQ:CRON) Spends $300 Million On CBD Skincare Businesses

Post Views: 218 Cronos Group Inc. (NASDAQ:CRON) has not had the best of runs in recent months, after starting the...

INDUSTRIAL HEMP1 month ago

Elev8 Brands, Inc. (OTCMKTS:VATE) A Potential Break Out Play On Sales Growth Boost

Post Views: 205 Elev8 Brands, Inc. (OTCMKTS:VATE) stock is a potential break out play as a flurry of positive developments...

INDUSTRIAL HEMP1 month ago

Medical Marijuana Inc. (OTCMKTS:MJNA) Eyes Fresh Gains On Improving Fundamentals

Post Views: 126 Medical Marijuana Inc. (OTCMKTS:MJNA) bounce back from all-time lows continues to gather pace on improving fundamentals. Investor’s...

INDUSTRIAL HEMP1 month ago

Sugarmade Inc. (OTCMKTS:SGMD) Turns To Hemp Production To Reinvigorate Growth Prospects

Post Views: 135 Sugarmade Inc. (OTCMKTS:SGMD) has made a strategic investment in Hempistry as it tries to reinvigorate its growth...

INDUSTRIAL HEMP8 months ago

Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis

Post Views: 110 Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative...

Advertisement

Whats Hot

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play